A Phase 1b Trial of X4P-001 Alone and With Pembrolizumab in Patients With Advanced Melanoma

Trial Profile

A Phase 1b Trial of X4P-001 Alone and With Pembrolizumab in Patients With Advanced Melanoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs X4P 001 (Primary) ; Pembrolizumab
  • Indications Malignant melanoma
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Sponsors X4 Pharmaceuticals
  • Most Recent Events

    • 10 Nov 2017 According to an X4 Pharmaceuticals media release, preliminary results from evaluable tumor biopsies of melanoma patients who received treatment with X4P-001-IO at 400 mg daily for 21 days were presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
    • 03 Nov 2017 According to an X4 Pharmaceuticals media release, first data from this trial will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
    • 11 Jan 2017 Planned End Date changed from 1 May 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top